Classify gall stones. Discuss the etiopathogenesis. Clinical features, investigation and treatment of acute calculous cholecystits.Describe etiology, clinical features, investigations, differential diagnosis and management of Gallstones***** ➢ Discuss obstructive jaundice with investigations and management***

Reading File
Now I'll run parallel searches across the medical library:
Finding Sources
Finding Sources
Reading File
Reading File
Good - substantial content returned. Let me read more of both files to get the full clinical picture:
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content from the textbooks. Let me fetch a couple of key images and get the obstructive jaundice management content:
Reading File
Loading Image
I now have comprehensive content from multiple authoritative textbooks. Let me compile the full, detailed answer.---

GALLSTONES (CHOLELITHIASIS) AND ACUTE CALCULOUS CHOLECYSTITIS


PART 1: CLASSIFICATION OF GALLSTONES

Gallstones affect 10-20% of adult populations in high-resource countries. More than 95% of biliary tract disease is attributable to gallstones. In the USA/Europe, over 80% are cholesterol or mixed stones; in Asia, 80% are pigment stones.

Three Main Types:

TypeCompositionKey Associations
Cholesterol stones>50% crystalline cholesterol monohydrateObesity, female sex, OCP, pregnancy, rapid weight loss, ileal disease
Black pigment stonesBilirubin polymer + calcium phosphate + calcium bicarbonate; <30% cholesterolHaemolysis (hereditary spherocytosis, sickle cell disease), cirrhosis, advancing age
Brown pigment stonesCalcium bilirubinate + calcium palmitate + calcium stearate + cholesterolBile stasis, infection (E. coli, Clonorchis sinensis, Ascaris lumbricoides), bile duct foreign bodies
Mixed stones contain 50-99% pure cholesterol with an admixture of calcium salts, bile acids, bile pigments and phospholipids.

PART 2: ETIOPATHOGENESIS OF GALLSTONES

Cholesterol Stone Formation - Three Steps:

Step 1 - Supersaturation of bile with cholesterol:
  • Cholesterol is insoluble in water and secreted from the canalicular membrane in phospholipid vesicles
  • When bile is supersaturated with cholesterol and/or bile acid concentrations are low, unstable unilamellar phospholipid vesicles form
  • Factors increasing cholesterol secretion: obesity, high-calorie diet, oral contraceptives, oestrogens (increase hepatic lipoprotein receptors and stimulate hepatic cholesterol synthesis)
  • Factors depleting bile acid pool: ileal disease (Crohn's), ileal resection, cholestyramine
Step 2 - Nucleation of cholesterol crystals:
  • Cholesterol monohydrate crystals nucleate from multilamellar vesicles
  • Nucleating factors include mucus, glycoproteins, and infection
Step 3 - Gallbladder hypomotility/stasis:
  • Abnormal gallbladder emptying aids aggregation of nucleated crystals
  • This is why removing stones without removing the gallbladder leads to recurrence
Factors in gallstone formation:
Factors associated with gallstone formation - Bailey and Love's

Risk Factors (The "5 F's" mnemonic expanded):

  • Fat - obesity, metabolic syndrome, hyperlipidaemia
  • Female - higher prevalence due to oestrogen exposure
  • Fertile - pregnancy increases biliary cholesterol secretion
  • Forty - increasing age; predominantly middle to older age
  • Fair - Northern Europeans, North/South Americans, Native Americans (Pima, Hopi, Navajo tribes up to 75%)
  • Additional: oral contraceptives, rapid weight reduction, gallbladder stasis, inborn bile acid metabolism disorders, total parenteral nutrition, vagotomy

Pigment Stone Pathogenesis:

  • Black stones: Unconjugated bilirubin increases due to haemolysis → precipitates as bilirubin polymer in concentrated supersaturated bile
  • Brown stones: Bacterial β-glucuronidase (from E. coli, Bacteroides) deconjugates bilirubin glucuronide → insoluble unconjugated bilirubinate precipitates in infected stagnant bile in ducts

PART 3: CLINICAL FEATURES OF GALLSTONES

Asymptomatic ("silent") gallstones - >80% of cases:
  • Prophylactic cholecystectomy generally NOT indicated
  • 20-year follow-up: only 18% develop biliary pain; mean yearly probability is 2% in first 5 years, declining to 0.5% by years 10-20
Symptomatic gallstones:
  • Right upper quadrant (RUQ) or epigastric pain, radiating to the back or right shoulder tip
  • Pain is typically dull, continuous, and severe (not truly "colicky") - lasts minutes to hours
  • Associated nausea, vomiting, anorexia
  • Pain often starts at night (wakes the patient)
  • Relieved when stone slips back into the gallbladder body
  • Dyspepsia, flatulence, fatty food intolerance (less specific symptoms)
Complications - clinical presentations:
  • Acute cholecystitis: fever, positive Murphy's sign, RUQ mass (omental wall-off)
  • Empyema of gallbladder: high fever, rigors, severely ill patient
  • Gangrene and perforation: peritonitis
  • Choledocholithiasis: obstructive jaundice (dark urine, pale stools, pruritus)
  • Cholangitis: Charcot's triad (RUQ pain + fever/rigors + jaundice); Reynolds' pentad adds shock + confusion
  • Pancreatitis: epigastric pain radiating to the back, elevated amylase/lipase
Differential Diagnosis of biliary colic:
  • Peptic ulcer disease / gastritis
  • Acute pancreatitis
  • Hepatitis (acute)
  • Right-sided renal colic
  • Myocardial infarction (inferior MI can mimic biliary pain)
  • Irritable bowel syndrome
  • Hiatus hernia / GORD
  • Appendicitis (atypical)

PART 4: INVESTIGATIONS FOR GALLSTONES

Bloods:

  • FBC - leucocytosis in cholecystitis (WBC >18,000/mm³ indicates moderate severity by Tokyo Guidelines)
  • LFTs - elevated ALP, GGT, conjugated bilirubin if CBD involvement; transaminases elevated in hepatitis/pancreatitis
  • Serum amylase/lipase - if pancreatitis suspected
  • CRP - inflammatory marker to assess severity
  • PT/INR - may be prolonged if jaundiced (Vitamin K deficiency)
  • Serum albumin - marker of nutritional status

Imaging:

InvestigationRoleSensitivity
Ultrasound (1st line)Detects gallstones, GB wall thickening (>4mm), pericholecystic fluid, acoustic shadowing, CBD diameter~95% for GB stones
MRCPBest non-invasive test for CBD stones, strictures, choledocholithiasis~95% overall for biliary obstruction
CT abdomenExcludes complications (perforation, abscess), detects CBD stones (less sensitive than MRCP), staging of malignancyHigh for masses >2cm
HIDA scan (hepatobiliary iminodiacetic acid)Functional assessment; non-filling = cystic duct obstruction (acute cholecystitis) when US equivocal~95% sensitivity for acute cholecystitis
ERCPTherapeutic gold standard for CBD stones - sphincterotomy, stone extraction, stentingAlso diagnostic for strictures
EUS (endoscopic ultrasound)Excellent for distal CBD, ampullary region tumors, FNA for tissue; sensitivity 84-91% for CBD stonesBetter than MRCP for small stones
Ultrasound criteria for acute cholecystitis:
  • Sonographic Murphy's sign
  • Gallbladder wall thickening >4mm
  • Pericholecystic fluid
  • Distended gallbladder with gallstones

PART 5: ACUTE CALCULOUS CHOLECYSTITIS

Pathogenesis:

Acute calculous cholecystitis accounts for 90% of all acute cholecystitis cases. The sequence is:
  1. Stone impaction in the cystic duct or gallbladder neck → outflow obstruction
  2. Chemical inflammation - mucosal phospholipases hydrolyze luminal lecithins to toxic lysolecithins → disrupts the protective glycoprotein mucus layer → bile salts exert direct detergent action on mucosa
  3. Prostaglandin release from distended gallbladder wall → mucosal and mural inflammation
  4. Distension and raised intraluminal pressure → compromised mucosal blood flow
  5. Bacterial superinfection (later phase) - bacteria from: E. coli, Klebsiella, Enterococcus, Bacteroides, Clostridium
  6. Progression → gangrenous cholecystitis → perforation → empyema/peritonitis

Clinical Features:

  • Onset: Progressive RUQ or epigastric pain lasting >6 hours (distinguishes it from biliary colic)
  • Fever: Low-grade initially; high fever suggests gangrenous cholecystitis or empyema
  • Nausea and vomiting
  • Anorexia, tachycardia, sweating
Physical signs:
  • Murphy's sign (pathognomonic) - RUQ tenderness exacerbated during inspiration when palpating the right subcostal region; the patient catches their breath
  • RUQ tenderness and guarding - tenderness, voluntary guarding
  • Palpable mass - inflamed gallbladder walled off by omentum
  • Jaundice (in ~20%) - due to CBD compression by periductal inflammation (Mirizzi syndrome) or concurrent choledocholithiasis

Complications:

  • Empyema of the gallbladder - pus filling the lumen; high fever, rigors, very tender mass
  • Gangrenous cholecystitis - wall necrosis; gas-forming organisms → emphysematous cholecystitis
  • Perforation - generalised biliary peritonitis or localised pericholecystic abscess
  • Fistula - cholecystoduodenal, cholecystocolic, or cholecystogastric
  • Gallstone ileus - large stone erodes into duodenum, causes small bowel obstruction at ileocaecal valve
  • Mirizzi syndrome - stone in cystic duct compresses common hepatic duct

Tokyo Guidelines 2018 - Severity Grading:

Grade I (Mild): Acute cholecystitis in a healthy patient with no organ dysfunction; mild inflammatory changes in the gallbladder
Grade II (Moderate): Any one of:
  • Elevated WBC >18,000/mm³
  • Palpable tender mass in RUQ
  • Duration of symptoms >72 hours
  • Marked local inflammation (gangrenous/emphysematous cholecystitis, pericholecystic abscess)
Grade III (Severe): Organ dysfunction in any one of:
  • Cardiovascular: hypotension requiring dopamine ≥5 μg/kg/min or any epinephrine
  • Neurological: decreased level of consciousness
  • Respiratory: PaO₂/FiO₂ ratio <300
  • Renal: oliguria; creatinine >2.0 mg/dL
  • Hepatic: PT-INR >1.5
  • Haematological: platelets <100,000/mm³

Management of Acute Calculous Cholecystitis:

Initial (non-operative) treatment:
  1. Nil by mouth + IV fluid resuscitation until pain resolves
  2. Analgesia - NSAIDs (diclofenac IM/IV reduces intraluminal pressure via prostaglandin inhibition), opioids (pethidine preferred over morphine to avoid Oddi spasm)
  3. IV Antibiotics - as cystic duct is blocked, serum concentration matters more than biliary concentration:
    • Mild-moderate: cefazolin, cefuroxime, cefoxitin, or ciprofloxacin
    • Severe: piperacillin-tazobactam or 3rd-generation cephalosporin + metronidazole
    • Add anaerobic cover if gangrenous/emphysematous cholecystitis suspected
  4. Monitoring: temperature, pulse, WBC, CRP
Investigations to confirm:
  • USG to confirm (first-line)
  • If jaundiced: MRCP to exclude choledocholithiasis
  • If complicated: CT scan
Surgical Management - Timing:
TimingRecommendationEvidence
Early cholecystectomy (within 72h-7 days)Preferred; safe if experienced surgeon availableShorter total hospital stay (9.6 vs 17.8 days combined RCT data)
Delayed/interval cholecystectomy (6 weeks later)If early surgery not feasible or Grade II with no deterioration26% failure requiring emergency surgery before 6 weeks
Emergency surgeryGrade III; imminent perforation; diagnostic uncertaintyUrgent
  • Laparoscopic cholecystectomy is the gold standard (higher conversion rate in acute vs. elective but still preferred)
  • Tokyo Guidelines algorithm: Grade I → early laparoscopic cholecystectomy; Grade II → early LC if experienced surgeon available, otherwise conservative + delayed LC; Grade III → ICU stabilisation first, then LC when stable or cholecystostomy as bridge
  • Percutaneous cholecystostomy - for Grade III patients unfit for surgery; tube drainage of gallbladder as a temporising measure


OBSTRUCTIVE JAUNDICE


DEFINITION

Obstructive (post-hepatic/cholestatic) jaundice is the clinical manifestation of impaired flow of conjugated bilirubin through the biliary tree into the duodenum. Total serum bilirubin is elevated, predominantly the direct (conjugated) fraction (>50% of total).

ETIOLOGY / CAUSES

Malignant (Painless, Progressive):

  • Carcinoma of the head of pancreas (most common malignant cause)
  • Cholangiocarcinoma (Klatskin tumour at hilum)
  • Carcinoma of the gallbladder
  • Ampullary carcinoma
  • Metastatic disease compressing the biliary system

Benign (often Painful, Fluctuating):

  • Choledocholithiasis (most common cause overall - painful, fluctuating)
  • Primary or secondary sclerosing cholangitis
  • Benign biliary strictures (post-operative, post-inflammatory)
  • Choledochal cyst
  • Parasites (Clonorchis sinensis, Ascaris)
  • Haemobilia
  • Pancreatic pseudocysts
  • Chronic pancreatitis (pseudotumoral)
  • Duodenal diverticulum / ampullary scarring

Congenital:

  • Biliary atresia
  • Caroli's disease
Key clinical pointer: Painful jaundice → likely stones; Painless progressive jaundice → likely malignancy (Courvoisier's law: a palpable non-tender gallbladder in the presence of jaundice is unlikely to be due to stones)

CLINICAL FEATURES

Symptoms:

  • Jaundice - yellow discolouration of skin, sclerae, mucous membranes
  • Dark urine (conjugated bilirubin - water soluble, excreted in urine → "Coca-Cola urine")
  • Pale/clay-coloured stools (absence of stercobilinogen)
  • Pruritus - due to bile salt deposition in skin; often severe
  • Fatigue
  • Abdominal pain - RUQ colicky pain in stones; epigastric pain in pancreatic cancer
  • Weight loss, anorexia - suggests malignancy
  • Fever and rigors - suggests cholangitis (Charcot's triad: pain + fever + jaundice)

Signs:

  • Icteric sclerae, jaundiced skin
  • Scratch marks (pruritus)
  • Palpable, non-tender gallbladder (Courvoisier's sign) → malignant obstruction
  • Hepatomegaly
  • Splenomegaly in portal hypertension
  • Cachexia, Virchow's node (left supraclavicular lymph node) - in GI malignancy
  • Hepatic flap/asterixis if hepatic failure developing

DIFFERENTIAL DIAGNOSIS

TypeExamplesBilirubinALPAST/ALTUrineStools
Pre-hepaticHaemolysis, spherocytosisIndirect ↑↑NormalNormalNormal (no bili)Normal/dark
HepaticViral hepatitis, cirrhosis, drugsBoth ↑Mildly ↑Markedly ↑↑Bilirubin+Variable
Post-hepatic (Obstructive)Stones, malignancyDirect ↑↑Markedly ↑↑↑Mildly ↑Dark (bilirubin+)Pale

INVESTIGATIONS

Blood Tests:

TestFinding in Obstructive Jaundice
Total bilirubinElevated; repeat every 3-4 days to monitor trend
Direct (conjugated) bilirubin>50% of total; markedly elevated
Serum alkaline phosphatase (ALP)3-4 fold elevation in 75% of cholestasis cases
GGT / 5'-nucleotidaseElevated (confirms hepatobiliary source vs bone)
AST/ALT (transaminases)Mildly elevated; very high levels (>1000 IU/L) suggest hepatocellular cause
Serum albuminLow in chronic disease / malnutrition
PT/INRProlonged (Vitamin K malabsorption); corrects with IV Vitamin K in post-hepatic jaundice (unlike hepatic jaundice) - this response differentiates the two
FBCAnaemia of malignancy; leucocytosis in cholangitis
Serum amylase/lipaseElevated in pancreatic pathology
CA 19-9, CEATumour markers for pancreatic and biliary malignancy
Alpha-fetoproteinHepatocellular carcinoma
Hepatitis serology (HBsAg, anti-HCV, HAV IgM)Exclude viral hepatitis
ANA, AMA (anti-mitochondrial Ab)Primary biliary cirrhosis (AMA+); autoimmune hepatitis

Imaging Investigations:

  1. Ultrasound (US) - FIRST LINE:
    • Detects biliary duct dilation; establishes level of obstruction in ~67% of cases
    • Sensitivity for CBD stones only 21-63% (poor for distal stones)
    • Shows liver parenchyma, gallbladder, hepatic/pancreatic masses
  2. MRCP (Magnetic Resonance Cholangiopancreatography):
    • Non-invasive test of choice for biliary anatomy
    • Sensitivity 95% for biliary obstruction; best for CBD stones
    • Differentiates strictures but distinguishing benign vs malignant can be challenging
    • No therapeutic capability
  3. CT abdomen/pelvis:
    • Excellent for pancreatic tumours >2cm, staging of malignancy
    • Identifies vascular involvement, lymphadenopathy, metastases
    • Less sensitive than MRCP for CBD stones
  4. EUS (Endoscopic Ultrasound):
    • Best for distal CBD, ampullary region, pancreatic head
    • Enables fine-needle aspiration (FNA): sensitivity 84-91%, specificity 71-100%
    • Can identify vascular invasion and lymph node metastases
  5. ERCP (Endoscopic Retrograde Cholangiopancreatography):
    • Primarily therapeutic (not just diagnostic)
    • Cannulation successful in >90% cases
    • Enables: sphincterotomy, stone extraction, balloon sweep, stent placement, brush cytology
    • Complications: pancreatitis, cholangitis, bleeding, perforation
  6. Percutaneous Transhepatic Cholangiography (PTC):
    • Used when ERCP fails or inaccessible anatomy
    • Allows external biliary drainage, internal stenting
  7. Liver biopsy:
    • Reserved for suspected parenchymal disease
    • Contraindicated if PT prolonged and unresponsive to Vitamin K, or platelets <50,000/mm³

MANAGEMENT OF OBSTRUCTIVE JAUNDICE

General Preoperative Preparation:

  1. Correction of coagulation:
    • IV Vitamin K₁ 20 mg → rapid normalisation of PT within 12-24 hours (if liver synthetic function intact)
    • Good response = post-hepatic obstruction (favourable surgical risk)
    • Poor response = hepatocellular disease
  2. Renal protection:
    • Jaundiced patients at high risk of hepatorenal syndrome
    • Aggressive IV fluid hydration pre- and post-operatively
    • Monitor urine output; consider mannitol infusion
    • Avoid nephrotoxic drugs
  3. Nutritional support - correct malnutrition, hypoalbuminaemia
  4. Antibiotics - treat concurrent cholangitis with broad-spectrum cover

Surgical mortality in jaundiced patients: ~20%; recognised risk factors:

  • Old age
  • Malnutrition
  • Ongoing biliary infection
  • Malignancy
  • High serum urea (renal impairment)

Definitive Management Based on Cause:

A. Choledocholithiasis (CBD stones):

  • ERCP + endoscopic sphincterotomy + stone extraction (first-line)
  • Basket or balloon retrieval of stones
  • Lithotripsy for large stones
  • Followed by laparoscopic cholecystectomy for the gallbladder

B. Malignant Obstruction (Pancreatic/Bile Duct Cancer):

Resectable disease (~20% of periampullary cancers):
  • Pancreaticoduodenectomy (Whipple's procedure) for periampullary/pancreatic head tumours
  • Preoperative biliary drainage: controversial - not proven to reduce operative mortality; however, needed if neoadjuvant chemotherapy is planned
Non-resectable disease:
  • Biliary decompression/palliation:
    • ERCP + stenting (first-line for distal obstruction)
      • Plastic stents: cheap but occlude every 3-4 months (biofilm formation); patency ~43 days
      • Self-expanding metallic stents (SEMS): wider bore, patency ~125 days; preferred for >6 months survival
      • Covered SEMS (cSEMS): prevent tumour ingrowth, removable; meta-analysis shows fewer adverse events vs uncovered SEMS
    • Percutaneous transhepatic drainage (when ERCP fails)
    • Surgical bypass (hepaticojejunostomy or choledochojejunostomy) if endoscopic approach not possible
  • Only 25-30% of liver volume needs to be drained for jaundice resolution
    • Right hepatic duct drains 50-55% of liver
    • Left hepatic duct drains 30-35%
    • Caudate lobe drains 10%

C. Benign Biliary Strictures (Bismuth Classification):

TypeLevelTreatment
ILow CHD stump >2 cmERCP dilation + plastic stents
IIProximal CHD stump <2 cmERCP or surgical repair
IIIHilar; confluence preservedHepaticojejunostomy
IVHilar; confluence lostComplex hepaticojejunostomy
VAberrant right sectoral ductSurgical
  • Endoscopic treatment: serial large-bore plastic stents exchanged every 3-4 months; success 74-90%, recurrence up to 30% at 2 years
  • Surgical hepaticojejunostomy (Roux-en-Y) for failed endoscopic treatment

D. Sclerosing Cholangitis:

  • Ursodeoxycholic acid (medically)
  • Dominant strictures: ERCP dilation + stenting
  • Liver transplantation for end-stage disease

Summary Algorithm for Obstructive Jaundice:

Jaundice suspected
      ↓
Blood tests (LFTs, bilirubin fractions, ALP, transaminases, PT)
      ↓
Ultrasound abdomen (1st line)
      ↓
Biliary dilation?
   YES                          NO
    ↓                            ↓
MRCP/CT/EUS              Consider hepatic/pre-hepatic cause
    ↓
Cause identified?
   Stones → ERCP + extraction    Malignancy → Resectable? → Whipple's
                                             → Non-resectable → ERCP stent / PTC
   Benign stricture → ERCP or surgical bypass

Sources:
  • Bailey and Love's Short Practice of Surgery, 28th Edition - Chapters on Gallstones, Acute Cholecystitis
  • Robbins, Cotran & Kumar Pathologic Basis of Disease - Gallbladder pathology
  • Sleisenger and Fordtran's Gastrointestinal and Liver Disease - Acute Cholecystitis, Obstructive Jaundice
  • Current Surgical Therapy, 14th Edition - Obstructive Jaundice evaluation and endoscopic management
  • Pye's Surgical Handicraft, 22nd Edition - Management of obstructive jaundice, preoperative preparation
This is a shared conversation. Sign in to Orris to start your own chat.